Tenaya Therapeutics

Update in progress

TNYA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tenaya Therapeutics, Inc. is a clinical‑stage biotechnology company focused on heart disease therapies in the United States. Its lead programs are TN-201, a gene therapy for MYBPC3‑associated hypertrophic cardiomyopathy (Phase 1b/2); TN-401, a gene therapy for PKP2‑associated ARVC (Phase 1b/2); and TN-301, a small‑molecule HDAC6 inhibitor for HFpEF (Phase 1). It uses gene addition, editing, silencing, and cellular regeneration, and collaborates with Alnylam for cardiovascular targets. Founded 2016, based in South San Francisco, CA.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive